Tibra Equities Europe’s Pfizer PFE Stock Holding History

Tibra Equities Europe’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-208,376	Closed	-$8.4M	–	395
2019 Q1	$8.4M	Sell	208,376 -15,072	-7%	-$604K	0.84%	25
2018 Q4	$9.25M	Buy	+223,448	New	+$9.28M	1.53%	17
2018 Q3	–	Sell	-356,725	Closed	-$12.3M	–	237
2018 Q2	$12.3M	Buy	+356,725	New	+$12.2M	1.84%	13

Other funds holding PFE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Tibra Equities Europe's PFE Position: Q2 2019 in Review

Tibra Equities Europe sold out of Pfizer (PFE) in Q2 2019, closing a stake of 208,376 shares — an estimated $8.4M sold.

Tibra Equities Europe first reported a position in PFE in Q2 2018 and held it in 3 quarters. The position peaked at $12.3M in Q2 2018. 2,378 funds tracked by Wall St. Rank hold PFE as of Q2 2019.

Tibra Equities Europe reported no remaining Pfizer position as of Q2 2019 after selling out during the quarter.
Tibra Equities Europe sold 208,376 Pfizer shares in Q2 2019, an estimated $8.4M.
Tibra Equities Europe first reported a position in Pfizer in Q2 2018 and held it in 3 quarters.
Tibra Equities Europe's Pfizer position peaked at $12.3M in Q2 2018.
2,378 funds tracked by Wall St. Rank held Pfizer as of Q2 2019.

Based on Tibra Equities Europe's 13F filing for Q2 2019, filed 1 Aug 2019.